Cure8 trial brief
This trial is testing an investigational anti-TL1A antibody (tulisokibart/MK-7240) as a potential new treatment for moderate to severe Crohn's disease. Results could affect future treatment options if the drug proves safe and effective.
Patients with moderate to severe Crohn's disease considering trial participation, clinicians who refer to trials, and researchers tracking investigational biologics (anti-TL1A).
This ClinicalTrials.gov record describes a randomized, interventional Phase 3 study currently recruiting participants with moderately to severely active Crohn's disease. The trial will compare one or more doses of tulisokibart to placebo with clinical remission (by Crohn's Disease Activity Index) as a primary efficacy endpoint.
Standard eligibility exclusions are listed, including recent bowel surgery, certain infections (active TB, HBV/HCV/HIV), recent cancer, prior exposure to this drug or other anti-TL1A antibodies, and other conditions. The record lists multiple U.S. study sites and notes the sponsor as Merck Sharp & Dohme LLC.
It is a trial record (not results), so no findings or safety conclusions are reported here.
This is a Phase 3 study registration without posted results. The record lists eligibility criteria and exclusion conditions; it does not provide efficacy or safety outcomes. Treat this as a trial opportunity/record, not evidence of benefit.
Review the original publication for the complete reporting, methods, and context.
This Cure8 brief is based on source text from the linked article. Cure8 is informational only and is not a substitute for professional medical advice, diagnosis, or treatment.
A successful Phase 3 trial could provide a new treatment option specifically studied in children with moderate‑to‑severe Crohn's disease, addressing a pediatric population often underrepresented in trials.
The article spotlights duvakitug and the anti‑TL1A drug class as potential new options for ulcerative colitis and Crohn’s disease, especially for treatment‑experienced patients. Biomarker‑driven studies could help...
These are multi‑year clinical results for a newly approved IL‑23p19 inhibitor (mirikizumab) showing sustained clinical and endoscopic benefit for many patients with moderate‑to‑severe Crohn’s disease, including some who...
